Quantbot Technologies LP Sells 108,680 Shares of DexCom, Inc. (NASDAQ:DXCM)

Quantbot Technologies LP cut its holdings in DexCom, Inc. (NASDAQ:DXCM) by 84.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,002 shares of the medical device company’s stock after selling 108,680 shares during the quarter. Quantbot Technologies LP’s holdings in DexCom were worth $1,556,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc purchased a new stake in DexCom in the 4th quarter worth approximately $25,000. Private Trust Co. NA raised its holdings in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 245 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after acquiring an additional 167 shares during the period. Larson Financial Group LLC boosted its holdings in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC purchased a new position in DexCom during the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 2.1 %

NASDAQ:DXCM opened at $75.32 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market cap of $29.43 billion, a P/E ratio of 52.67, a P/E/G ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a 50-day simple moving average of $83.24 and a two-hundred day simple moving average of $77.07.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Kevin R. Sayer sold 32,498 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now directly owns 372,029 shares of the company’s stock, valued at $26,183,401.02. This trade represents a 8.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 13,000 shares of the business’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the transaction, the executive vice president now directly owns 105,602 shares of the company’s stock, valued at approximately $7,432,268.76. This trade represents a 10.96 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,009 shares of company stock valued at $8,044,178. Corporate insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the subject of several research analyst reports. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Morgan Stanley raised their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and raised their target price for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Citigroup upped their price target on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.